glp-1 safety concerns Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity Unauthorized GLP-1 Knockoffs Risk Patient

TRICARE still covers Ozempic and Mounjaro for type 2 diabetes across all plans

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily used to manage type 2 diabetes mellitus and, more recently, for weight management in specific patient groups

Large-scale pharmacovigilance analyses, such as those of the WHO VigiBase and Food and Drug Administration Adverse Event Reporting System, demonstrate that certain SSRIs carry disproportionate reporting signals, underscoring the need for individualized prescribing and long-term monitoring

Both are approved by the FDA for weight loss in adults with obesity or overweight plus a weight-related condition

In China, beyond the in-market products such as semaglutide and tirzepatide and promising global pipeline assets including orforglipron (oral), MariTide (monthly injectable) and retatrutide (triple agonist), a range of China-only molecules is also emerging with strong competitiveness (see Table 2)

However, the collected body of evidence does not fully support its clinically relevant antidepressant benefit [165]